Imetelstat Implodes in Breast Cancer Trial, Geron Swoons
The melancholy on the Geron Corp. conference call early Monday morning was palpable after the company disclosed its decision to halt the Phase II study of imetelstat in metastatic HER2-negative breast cancer after an unplanned interim analysis revealed a greater number of deaths in the treatment arm than the comparator arm.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter